Redacted version of CHI report could be published this week, Health Minister says
The internal investigation, the details of which were first reported by the Sunday Times and subsequently seen by
The Journal
and other media outlets, came about after concerns were raised about how waiting list initiatives were being carried out at a hospital run by CHI.
It detailed how a consultant was paid €35,800 by the hospital after money was received from the National Treatment Purchase Fund (NTPF) to help cut long waiting lists.
The HSE has
referred the report to gardaí
and the Irish Medical Council.
Jennifer Carroll MacNeill has
previously called
for a redacted version of the report to be published.
Speaking on Newstalk's Anton Savage Show this morning, she said she had not published the report after checking with the Attorney General because she has 'no legal basis' to do so.
'This was an internal human resources-type report going into some very serious cultural issues, and the people who participated in it, nurses, junior doctors and so on, they participated in it on that basis, in a confidential way,' she said.
Carroll MacNeill said the report reflects what some staff said in confidence and that some of them would be identifiable
In the normal course, you'd never publish something like that, but the issues in this are of such seriousness that in the broader public interest, a version of it must be published.
She said that CHI are reflecting on how to publish the report 'responsibly' so that it 'tells the maximum story behind it and the steps of what has been taken next'.
Advertisement
When asked if she knows when this will be published, she said: 'I suspect it will be this week.'
The Fine Gael TD said it is important that the people 'who might have given descriptions about what they were feeling and perhaps some of the pressures they felt' are appropriately protected.
On hospital governance, Carroll MacNeill said she had a lot of questions about the different governance structures across the country.
'Ireland is a small country. It's five and a half million people. We spend a very significant amount of our taxpayers money on health, quite appropriately, but we need to make sure that we're getting the best value for that.'
She said CHI was formed in an effort to create a single entity that would bring Temple Street and St James's hospitals together, adding that it has 'done that and has brought it to a certain point'.
'There's no question about that, but I do think that there's very much more work to be done to integrate a single pediatric system.'
National Children's Hospital
The Minister was also asked whether it was appropriate that CHI are permitted to run the new National Children's Hospital (NCH). The earliest date that the hospital will now be open to patients is June 2026.
'I think we'll be reflecting on that sort of policy structure over the next year,' she said, adding that her first concern is that the NCH is opened at the earliest possible date.
She said that there are 140 consultants within CHI, and that these issues have been created from 'a very small proportion'.
'I am a parent of a child in CHI, many, many others are and they know that it's a very good service. It's very, very functional. But that doesn't mean we don't need to get deep into these problem areas.'
Last month, Carroll MacNeill appointed two HSE board members to the board of CHI after three of its members resigned following the release of an
independent review into children's hip surgeries
at three CHI hospitals.
Related Reads
HSE to refer unpublished Children's Health Ireland report to gardaí and Medical Council
Health Minister calls for CHI report on consultant misuse of waiting list system to be published
Three members of Children's Health Ireland board resign after review into hip surgeries
'I do have another a number of vacancies which I think will need to be filled, and I think we will reflect on that in policy terms over the next number of months,' she said.
She said the Government would keep 'a steady focus' on the delivery of services, the implementation of reforms where they need to happen and planning for the NCH.
'But I am watching and managing this very carefully from a medium-term policy perspective,' she added.
National Treatment Purchase Fund
The matter of the National Treatment Purchase Fund (NTPF) was also raised. The NTPF provides funding for patients on waiting lists to get treatment in both public and private settings.
It pays for clinics to be set up in public hospitals outside of normal working hours, i.e on weekends, wherein staff already working at the hospital are paid additionally to carry out extra work. This is known as 'insourcing'.
The NTPF had suspended funding to CHI hospitals over concerns raised in an internal audit, related to an insourcing clinic at the hospital. On Wednesday, it
cut funding to another public hospital temporarily
after finding ' potential financial irregularities' in relation to NTPF-funded insourcing work.
Carroll MacNeill said that an audit of insourcing that she and HSE chief Bernard Gloster commissioned has been completed and that she expects to see the results 'possibly' in the next two to three weeks.
She said the matter needs 'very serious and careful analysis', as does the issue of insourcing more broadly 'because of how it intersects with getting the best productivity within the public system'.
'We cannot have a fully public system and also be creating these other incentives. We cannot cut off these other incentives overnight because of the impact on patient care, but by God, we're going to be weaning ourselves off them.'
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
Learn More
Support The Journal
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
3 days ago
- Irish Times
Inquiry begins into historical use of anti-epileptic drug and effects on pregnant women
The historical licensing and use of the anti-epileptic drug sodium valproate for women of childbearing age will be examined as part of an inquiry that started its work on Tuesday. Mothers of children diagnosed with foetal valproate spectrum disorder (FVSD) have long called for a public inquiry to investigate why they were not warned about the risks of taking the drug while pregnant . FVSD is caused by exposure in the womb to valproic acid, which is the key ingredient in sodium valproate, better known in Ireland as Epilim. An Irish Medical Journal study published in 2021 said diagnosing the condition was 'difficult' due to the lack of any specific diagnostic test or biomarker. READ MORE However, it said dysmorphic facial features, neural tube defects, congenital heart disease and cleft lip were among the most commonly associated characteristics. The study noted that Irish public health data suggested 3,126 babies were potentially exposed to sodium valproate before birth between 1975 and 2015. Minister for Health Jennifer Carroll MacNeill said the inquiry would give people directly affected by sodium valproate an 'opportunity to have their voices heard'. She welcomed the commencement of the inquiry, which was announced last year by her predecessor, Stephen Donnelly. She said she recently met the Organisation Anticonvulsant Syndromes Ireland (OACS Ireland), a campaign group dedicated to supporting and advocating for families affected by foetal anticonvulsant syndrome. 'I know this is an important day for them and the families they represent,' Ms Carroll MacNeill said. 'I have every confidence that the chair will conduct an independent and fair inquiry and finally get answers for those affected and their families.' The inquiry, involving three distinct phases, is chaired by barrister Bríd O'Flaherty. The Department of Health said it envisaged she would spend 12 to 18 months conducting an 'independent, fair and rigorous process'. The first phase will establish a timeline for the use of sodium valproate in women of childbearing potential in the State, including information on regulation, prescribing, dispensing and safety information issued. The inquiry will document the evolution of the drug's regulation and practices around its control. The second phase will focus on oral statements from people diagnosed with FVSD, their mothers and other family members. The final strand will assess the health service's capacity to respond to safety issues related to the use of anti-seizure medications in women of child-bearing potential.
The Journal
3 days ago
- The Journal
'The real work starts now': Long-awaited inquiry into drug that causes birth defects begins
A LONG-AWAITED inquiry into an antiepileptic drug that can cause serious birth defects if used during pregnancy has finally gotten underway, nearly five years after the Government committed to holding one. The non-statutory inquiry into the historical licensing and use of sodium valproate will have three strands, with statements from those affected by the drug expected to be taken from September. Health Minister Jennifer Carroll MacNeill has welcomed the commencement, saying that it 'will give those directly affected by sodium valproate an opportunity to have their voices heard'. The inquiry was approved by Cabinet in July 2023 , almost three years after the then-health minister Stephen Donnelly committed to holding a probe into the drug. Barrister and mediator Bríd Flaherty was announced as the chairperson of the non-statutory inquiry in June 2024, with Donnelly saying at the time that he intended to get it up and running ' in a matter of weeks ', but this did not take place. The delay in the commencement of the inquiry is understood to have been due to the fact that the data regulations had yet to be finalised. Sodium valproate can cause serious birth defects and developmental disorders to an infant if taken during pregnancy and women have been advised against using it unless no other treatment is possible. The drug was prescribed in Ireland and elsewhere for years after the danger was discovered and many countries are now investigating its use. Today, the Health Products Regulatory Authority (HPRA) states that the drug can cause birth defects and problems with the development and learning of the child if their mother takes it during pregnancy. Advertisement Children exposed to the drug while in the womb are at a high risk of serious developmental disorders (in up to 30-40% of cases) and congenital malformations (in approximately 10% of cases). Symptoms of fetal valproate syndrome (FVS) vary, but can include characteristic facial features, spina bifida, congenital heart defects, cleft lip and/or cleft palate, genital abnormalities, skeletal abnormalities and developmental delay. The drug's risk to infants has been made public in recent years, but campaigners in the UK found documents in the National Archives that indicated health regulators were aware of the risk as far back as 1973 but chose not to warn patients, saying it 'could give rise to fruitless anxiety'. A HSE report published in 2018 estimated that 1,250 children have been affected by valproate since 1975 in Ireland. In 2021, an investigation by The Journal Investigates found that around 3,000 Irish children were potentially harmed by exposure to the drug in the womb. Read The Journal Investigates's investigation into the valproate scandal . Last January, doctors began informing men of the potential risks that taking sodium valproate can have on their future children before prescribing it to them following precautionary measures recommended by the European Medicines Agency. Inquiry The Department of Health said the inquiry will have three strands. The first strand will be the review phase, which will establish a timeline for the use of sodium valproate in Ireland 'in women of childbearing potential including information on regulation, prescribing, dispensing and safety information issued'. The inquiry will seek to document the evolution of the regulation of the drug and the practices around the control of it. The Department said the inquiry 'will have responsibility to request documentation and submissions from a range of stakeholders', and the chair will record 'difficulties encountered where such requests are refused as part of their reporting function'. The second strand of the inquiry will seek oral statements from anyone impacted by the use of the drug, including people diagnosed with Foetal Valproate Spectrum Disorder (FVSD), their mothers and other family members who may wish to participate. This is anticipated to begin in September. Anyone who wishes to take part in this strand of the inquiry can register their interest on its website . These sessions will be held in private, and other stakeholders may also be invited to provide oral statements in separate sessions. Related Reads Chairperson appointed to probe into drug that causes birth defects after almost a year's delay Six months on, chairperson yet to be appointed to inquiry into drug that causes birth defects Doctors to inform men taking sodium valproate of risks to unborn children The third strand will focus on assessing the health service's current capacity to respond to safety issues 'related to use of anti-seizure medications (ASMs) in women of childbearing potential'. This will involve an assessment of the current systems in place to respond, disseminate and implement measures that address these potential safety issues, the development of other recommendations regarding current control systems for sodium valproate and other ASMs, and the services and supports for those impacted by sodium valproate. The Department said the results of this assessment will inform future service development. A communications campaign will be launched in the coming weeks to raise public awareness and support engagement with the inquiry. 'The real work starts now' Last month, when the inquiry had yet to commence, the Organisation for Anticonvulsant Syndromes (OACS) Ireland group, which supports families that have been impacted by the drug, told The Journal that it was seeking a meeting with the Minister for Health to discuss the status of the inquiry. Today, Carroll MacNeill said she was 'grateful' to meet with OACS Ireland recently 'and I know this is an important day for them and the families they represent'. 'I have every confidence that the Chair will conduct an independent and fair Inquiry and finally get answers for those affected and their families,' she said. In a statement, chair of OACS Ireland Karen Keely, whose three adult sons have been affected by exposure to sodium valproate, said: 'The real work starts now. 'The Inquiry will draw a spotlight on a public health issue which, whilst life-changing, is perhaps not as well known or understood by the public as other public health issues,' Keely said. Solicitor Ciara McPhillips, who represents OACS Ireland within the inquiry process, said: 'Together with OACS, I look forward to working with all stakeholders under the stewardship of the Chair to ensure those affected understand how it arose that women and mothers were prescribed a medication, which whilst very effective in preventing seizures, was so devastatingly detrimental to their children – many of whom will never live independent lives.' Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Extra.ie
4 days ago
- Extra.ie
Cutting costs: Vasectomies could soon be free across Ireland as men urged to 'step up'
Vasectomies may soon be offered for free across the country, the Health Minister has confirmed. Jennifer Carroll MacNeill was responding to a question by Labour's Marie Sherlock TD, who told the Dáil that it was time for men to 'step up' and stop relying on women to use contraceptives. Responding to a parliamentary question from Ms Sherlock, Ms Carroll MacNeill agreed that there was 'significant inequity of access' to vasectomy, both geographically and based on ability to pay, and that the Government is now considering free access to vasectomies across the country. Jennifer Carroll MacNeill. Pic: Stephen Collins/ Collins Photos She said that the Department of Health's National Sexual Health Strategy is 'committed to scoping the potential for expanding access to male and female sterilisation', including vasectomies for men. The Minister also said that a strategy will be created 'as soon as possible in 2025.' Vasectomies are currently available without cost to some medical cardholders. Ms Sherlock told the Dáil: 'The responsibility for family planning shouldn't just fall on the woman's shoulders. There's a simple, relatively pain-free procedure that a man recovers from within a very few short hours, but obviously it has a transformative impact on the family. Marie Sherlock. Photo: RTÉ. 'We have to make sure in the whole family planning conversation that men step up and take their responsibility seriously. There's a real inequality of access to the service, and particularly outside of the main urban areas,' she said. 'There's a crucial issue here about how we encourage and incentivise doctors to take on the service, and crucially, then from the department of health perspective, that there is a decent geographical spread of these services across the country.' However, Aontú leader, Peadar Tóibín, last night questioned whether the Government should be offering free vasectomies while Ireland's fertility rates continue to plunge. Peadar Tóibín. Pic: Fran Veale Mr Tóibín said: 'There are major questions in relation to where the Government is going in relation to this. So what we've seen in the last decade is a collapse in the fertility levels. They're lower now than the replacement rate, which means there's going to be significantly fewer children in future than there were in the past.' The fertility rate for 2024 stood at 1.5, a decrease of 0.5 from the 2014 fertility rate of 2.0. This is still higher than the European average, which stands at 1.38 births per woman in the EU. In Malta, the fertility rate stands at 1.06, compared to 1.81 in Bulgaria. Mr Tóibín warned that Ireland will create 'lopsided demographics, which means there will be fewer young people to be able to work, to provide the taxes to pay the pensions for people into the future. 'Good governance means a balanced demographics, and actually, at this moment in time, that means encouraging families to have more children. 'There's no doubt that the housing crisis is hammering families. They're delaying having children, and they're living, oftentimes, young couples in their parents' box room, which means that they can't have children and it's later and later until people are getting mortgages.' He went on: 'The cost of childcare is prohibitive for many, many people, and also the abortion rates have increased from about 3,000 abortions a year in 2018 to spiking well over 10,000 now.' 'All of these issues are pushing down the number of children that have been born. We should be giving families the economic confidence to be able to raise their children, to be able to have children, and so that we have a vibrant society and economy into the future.' Ryan Murphy, the operations manager at Sandyford, Dublin-based clinic said that vasectomies could not be accessed in multiple areas of the country, creating a 'two-tier system'.
